Long-term health-related burden of adult congenital heart diseases in Hong Kong.

abstract：OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

journal_title：Journal of medical economics

authors： Langkilde LK,Bergholdt Asmussen M,Overgaard M

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients w...

journal_title：Journal of medical economics

authors： Godman B

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVES:To determine the cost effectiveness of sevelamer vs calcium carbonate in patients with chronic kidney disease and not on dialysis (CKD-ND) from the perspective of the National Health Service (NHS) in the UK. METHODS:A Markov decision analytic model was developed to estimate (1) total life years (LYs), quali...

journal_title：Journal of medical economics

authors： Thompson M,Bartko-Winters S,Bernard L,Fenton A,Hutchison C,Di Iorio B

更新日期：2013-01-01 00:00:00

abstract：:Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model w...

journal_title：Journal of medical economics

authors： Torres A,Bassetti M,Welte T,Rivolo S,Remak E,Peral C,Charbonneau C,Hammond J,Ansari W,Grau S

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

journal_title：Journal of medical economics

authors： He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

更新日期：2017-09-01 00:00:00

abstract：OBJECTIVE:This study evaluated the overall burden of illness of chemotherapy-induced nausea and vomiting (CINV) and associated all-cause costs from a hospital's perspective (costs to the hospital) in patients with cancer treated with chemotherapy (CT) in the US hospital outpatient setting. METHODS:Patients with a canc...

journal_title：Journal of medical economics

authors： Craver C,Gayle J,Balu S,Buchner D

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:The objective of the current study was to propose an alternative method for measuring individual operator and peer volumes to use as predictors for adverse outcomes. STUDY DESIGN:A retrospective analysis was performed to assess the volume-outcome relationship for percutaneous coronary intervention (PCI) perf...

journal_title：Journal of medical economics

authors： Xie Y,Rizzo JA,Brown DL

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Growing financial pressure on US dialysis providers requires economic efficiency considerations. The objective of this study was to examine short-term economic efficiencies of a cinacalcet-based treatment approach for secondary hyperparathyroidism. METHODS:This study retrospectively assessed cost per bioche...

journal_title：Journal of medical economics

authors： Belozeroff V,Lee A,Tseng S,Chiroli S,Campbell JD

更新日期：2013-09-01 00:00:00

abstract：:Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment.Materials and methods: This retrospective analysis used data from three large ad...

journal_title：Journal of medical economics

authors： Samuelsen C,Lim J,Golembesky A,Shrestha S,Wang L,Griebsch I

更新日期：2020-01-01 00:00:00

abstract：PURPOSE:To evaluate the insulin wastage and associated acquisition costs when switching from individual patient supply (IPS) of 3-mL pens of rapid-acting insulin (RAI) aspart to floor stock (FS) dispensing of 3-mL vials of RAI lispro, and with conversion from IPS of 3-mL pens to centralized unit dose (CUD) of 10-mL via...

journal_title：Journal of medical economics

authors： Kelton KA,Perk S,Loveland S,Perez-Nieves M,Fu H,Peng X

更新日期：2017-05-01 00:00:00

abstract：OBJECTIVE:Reduction in health-related quality of life is common in children born small for gestational age (SGA) or children with growth hormone deficiency (GHD). Growth hormone treatment with somatropin in these children leads to normalisation of height. The aim of this study was to determine whether somatropin is a c...

journal_title：Journal of medical economics

authors： Christensen T,Fidler C,Bentley A,Djurhuus C

更新日期：2010-03-01 00:00:00

abstract：OBJECTIVE:To assess predictors and costs of multiple sclerosis (MS) relapse, a potential outcome measure in payer-manufacturer risk-sharing agreements for disease-modifying drugs (DMDs). METHODS:A retrospective cohort analysis of medical/pharmacy claims was used. Study patients had ≥1 DMD (interferon beta, glatiramer,...

journal_title：Journal of medical economics

authors： Lage MJ,Carroll CA,Fairman KA

更新日期：2013-09-01 00:00:00

abstract：AIMS:In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) from the US payer perspective, (2) simulated how savings enable, on a budget-neutral b...

journal_title：Journal of medical economics

authors： MacDonald K,McBride A,Alrawashdh N,Abraham I

更新日期：2020-10-24 00:00:00

abstract：OBJECTIVE:Basal insulin analogs are well established in the treatment of type 1 diabetes in Germany. However, little is known about their economic impact. The aim of this study for an adult population was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting...

journal_title：Journal of medical economics

authors： Pfohl M,Schädlich PK,Dippel FW,Koltermann KC

更新日期：2012-01-01 00:00:00

abstract：AIM:To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment ...

journal_title：Journal of medical economics

authors： Igarashi A,Igarashi A,Graham CN,Gilloteau I,Tani Y

更新日期：2018-10-26 00:00:00

abstract：BACKGROUND:Inhibitor development to factor VIII (FVIII) hemophilia therapy results in increased complications and substantial economic costs. The SIPPET study, the first randomized controlled trial to compare the immunogenicity of plasma-derived FVIII (pdFVIII)/von Willebrand factor (VWF) and recombinant-DNA-derived FV...

journal_title：Journal of medical economics

authors： Neufeld EJ,Sidonio RF Jr,O'Day K,Runken MC,Meyer K,Spears J

更新日期：2018-08-01 00:00:00

abstract：OBJECTIVE:Prostate cancer is a leading cause of cancer death in men in the US. Castration-resistant prostate cancer (CRPC) is an advanced form of the disease and has a poor prognosis and limited treatment options. The objective of this study was to identify patients with CRPC from a medical claims database, and determi...

journal_title：Journal of medical economics

authors： Alemayehu B,Buysman E,Parry D,Becker L,Nathan F

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

journal_title：Journal of medical economics

authors： Papadopoulos G,Hunt S,Prasad M

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Efficient use of government funding has been increasingly relevant for the success and sustainability of ongoing health-system reform in China; however, as there is no generic substitution policy, patients and basic health-insurance programs pay more for public-preferred brand originators. Such phenomenon is...

journal_title：Journal of medical economics

authors： Sun J,Ren L,Wirtz V

更新日期：2016-09-01 00:00:00

abstract：OBJECTIVE:To construct a value-based healthcare system for rural Chinese hypertensive patients through an increasing outpatient care reimbursement ratio. METHODS:This comparative study sampled two similar counties, Dangyang County and Zhijiang County, in Hubei Province of China, as the intervention group and the contr...

journal_title：Journal of medical economics

authors： Miao Y,Yuan X,Gu J,Zhang L,He R,Sandeep S,Wu J

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND AND AIMS:Randomized controlled trials have shown that a once-daily prolonged-release (PR) tacrolimus formulation (PR tacrolimus; Advagraf * ), is non-inferior to a twice-daily immediate-release (IR) tacrolimus formulation (IR tacrolimus; Prograf † ) in terms of biopsy-proven acute rejection, graft failure an...

journal_title：Journal of medical economics

authors： Muduma G,Odeyemi I,Pollock RF

更新日期：2014-07-01 00:00:00

abstract：OBJECTIVE:To carry out a cost-utility analysis comparing initial treatment with solifenacin 5 mg/day vs oxybutynin immediate-release (IR) 15 mg/day for the treatment of patients with overactive bladder (OAB) from the perspective of the U.K. National Health Service (NHS). METHODS:A Markov model with six health states w...

journal_title：Journal of medical economics

authors： Hart WM,Abrams P,Munro V,Retsa P,Nazir J

更新日期：2013-10-01 00:00:00

abstract：OBJECTIVE:Iso-osmolar Iodixanol is associated with a lower rate of contrast-induced acute kidney injury (CI-AKI) in patients at increased risk compared to low-osmolar contrast media (LOCM). The aim of this study was to assess the financial consequences of CI-AKI risk reduction in patients undergoing coronary angiograph...

journal_title：Journal of medical economics

authors： De Francesco M,Ronco C,Wacinski PJ,Wessely R,Hernández F,Lamotte M

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...

journal_title：Journal of medical economics

authors： McGuire A,Martin M,Lenz C,Sollano JA

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:To estimate health-related quality of life (HRQoL) in non-growth hormone deficient (GHD) small for gestational age (SGA) children before and after growth hormone (GH) treatment to adult height (AH). METHODS:This was a multicentre, two-arm trial. Following an initial 2-year double-blind study period, patients...

journal_title：Journal of medical economics

authors： Bannink E,Djurhuus CB,Christensen T,Jøns K,Hokken-Koelega A

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline therapy for stage III/IV classical Hodgkin lymphoma. This analysis evaluated the cost-effectiveness o...

journal_title：Journal of medical economics

authors： Delea TE,Sharma A,Grossman A,Eichten C,Fenton K,Josephson N,Richhariya A,Moskowitz AJ

更新日期：2019-02-01 00:00:00

abstract：:Objectives: Aging populations are contributing to an increased volume of osteoporotic fractures. The goals of this study were to (1) develop a scorecard on epidemiological burden, policy framework, service provision, and service uptake for osteoporosis in Saudi Arabia and (2) estimate the direct costs of managing oste...

journal_title：Journal of medical economics

authors： Aziziyeh R,Garcia Perlaza J,Saleem N,Sadat-Ali M,Elsalmawy A,McTavish RK,Duperrouzel C,Cameron C

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

journal_title：Journal of medical economics

authors： Seetasith A,Wong W,Tse J,Burudpakdee C

更新日期：2019-05-01 00:00:00

abstract：AIM:Renal failure is a growing public health problem, and is mainly treated by hemodialysis. This study aims to estimate the societal costs of hemodialysis in Lebanon. METHODS:This was a quantitative, cross-sectional cost-of-illness study conducted alongside the Nutrition Education for Management of Osteodystrophy tri...

journal_title：Journal of medical economics

authors： Rizk R,Hiligsmann M,Karavetian M,Salameh P,Evers SM

更新日期：2016-12-01 00:00:00

abstract：OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...

journal_title：Journal of medical economics

authors： Rubin RJ,Glaspy JA,Adams JL,Mafilios MS,Wang SM,Viswanathan HN,Kallich JD

更新日期：2008-01-01 00:00:00